Drug Profile


Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Furans; Naphthoquinones; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Solid tumours
  • Phase I Gastrointestinal cancer; Haematological malignancies

Most Recent Events

  • 07 Jul 2017 Boston Biomedical terminates the phase III CanStem43L trial due to change of treatment landscape and evolving standard of care in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and Spain (PO) (NCT02826161)
  • 30 Jun 2017 Adverse event data from two phase Ib/II trials in Pancreatic cancer and Colorectal cancer presented at the 19th World Congress on Gastrointestinal Cancer (WCGC-2017)
  • 28 Jun 2017 Sumitomo Dainippon Pharma completes enrolment in the phase III BRIGHTER trial for Colorectal cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Japan, South Korea, Lithuania, Poland, Romania, Russia, Spain, United Kingdom and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top